Key clinical point: A blood test that seems almost as good as amyloid PET scanning, the gold standard, for detecting asymptomatic amyloid plaques in the brain could be on the market in 2-3 years.

Major finding: The plasma ratio of amyloid-beta 42 peptide to amyloid-beta peptide 40 identified people who were PET positive and PET negative for amyloid with an area under the curve of 0.88 (95% confidence interval, 0.82-0.93).

Study details: The assay was tested in 158 people in their 60s and 70s.

Disclosures: The test is being commercialized by the lead investigator’s colleagues. She is not involved in the efforts.